Bayer Reports Positive Pediatric Data for Low-Dose MRI Contrast Agent Gadoquatrane
Bayer has released late-breaking results from the QUANTI Pediatric study, showing that its investigational low-dose MRI contrast agent gadoquatrane met all primary and secondary endpoints in children.


















